A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Golimumab (Primary) ; Guselkumab (Primary) ; Guselkumab (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Acronyms VEGA
- Sponsors Janssen Research & Development; Janssen-Cilag
- 03 Oct 2019 Planned End Date changed from 24 Feb 2022 to 7 Sep 2021.
- 09 Jul 2019 According to a Celsius Therapeutics media release, company announced a collaboration with Janssen Biotech Inc. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify predictive biomarkers of response from this study.
- 03 Dec 2018 Status changed from not yet recruiting to recruiting.